IMNM - Stock Analysis & Overview

About Immunome, Inc.

Biotechnology

Healthcare

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Immunome, Inc. Key Metrics

Market Cap: $976M
52 Weeks Low: $6.65
52 Weeks High: $30.96
P/B: 3.84x
P/E: -3.71x
P/S: 90.49x

Upcoming Events

IMNM Analyst Forecasts

‌

IMNM Financials

IMNM Income Statement Key Metrics

Revenue(TTM)10.78 M
Gross Profit(TTM)9.42 M
EBITDA(TTM)-270.40 M
Net Income(TTM)-262.59 M
EPS Diluted(TTM)-17.74

Decode IMNM's Latest Earnings Call with Ease

Tap 'Generate' for a crystal-clear,
AI-crafted summary and stay ahead in the investment game!

IMNM earnings and revenue history

Gross Profit Margin vs Peers

Profit margin ratio of IMNM (0.948) is higher than the average of its peers (-0.150).

Net Profit Margin vs Peers

Net profit margin ratio of IMNM (-7.619) is lower than the average of its peers (-3.232).

IMNM Return on Equity

See how efficiently IMNM generates profit for it's shareholders.

-89.09%

100

Poor

Average

Strong

Return on Equity vs Peers

Return on Equity ratio of IMNM (-0.891) is lower than the average of its peers (-0.144).

Return on Equity Growth

IMNM's Return on Equity has shown poor growth over the past 10 years, increasing by only -19.16%.

IMNM Revenue Growth

See how IMNM has grown it's revenue over the past 10 years.

‌

Revenue Growth

IMNM's revenue has grown significantly over the past 10 years, increasing by over 0%.

Immunome, Inc.

Page title

Section title